Live price temporarily unavailable.
Fractyl Health (GUTS) is a Health Care company. Latest news and coverage below.
Fractyl Health revenue & net income history (FY2023–FY2025)
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Revenue | $120.0K | $93.0K | $0 |
| Growth (year over year) | — | −22.5% | −100.0% |
| Gross profit | $43.0K | $43.0K | $0 |
| Gross margin | 35.8% | 46.2% | — |
| Operating income | −$50.8M | −$93.5M | −$96.8M |
| Operating margin | −42363.3% | −100571.0% | — |
| Net income | −$77.1M | −$68.7M | −$141.0M |
| Net margin | −64242.5% | −73864.5% | — |
| EPS (diluted) | −$45.29 | −$1.62 | −$1.86 |
| Balance sheet | |||
| Cash and equivalents | $33.2M | $67.5M | $81.5M |
| Total assets | $76.2M | $108.1M | $121.4M |
| Total liabilities | $113.9M | $79.7M | $111.9M |
| Shareholders' equity | −$325.1M | $28.4M | $9.46M |
| Cash flow | |||
| Operating cash flow | −$42.8M | −$65.5M | −$90.3M |
| Capital expenditure | $359.0K | $1.76M | $557.0K |
| Free cash flow | −$43.2M | −$67.3M | −$90.9M |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $14.0K | — | — | — | — | — | — | — |
| Growth (year over year) | −61.1% | — | — | — | — | — | — | — |
| Gross profit | $7.00K | — | — | — | — | — | — | — |
| Gross margin | 50.0% | — | — | — | — | — | — | — |
| Operating income | −$23.8M | — | −$24.8M | −$26.1M | −$22.7M | −$23.3M | −$20.8M | −$19.1M |
| Operating margin | −169957.1% | — | — | — | — | — | — | — |
| Net income | −$23.2M | — | −$23.7M | −$27.9M | −$45.6M | −$43.7M | $9.22M | −$25.5M |
| Net margin | −165521.4% | — | — | — | — | — | — | — |
| EPS (diluted) | −$0.48 | — | −$0.49 | −$0.57 | −$0.71 | −$0.09 | $0.06 | −$0.16 |
| Balance sheet | ||||||||
| Cash and equivalents | $84.7M | $67.5M | $42.1M | $22.3M | $77.7M | $81.5M | $63.2M | $47.1M |
| Total assets | $126.9M | $108.1M | $83.0M | $62.0M | $114.3M | $121.4M | $99.4M | $82.0M |
| Total liabilities | $76.6M | $79.7M | $76.7M | $80.2M | $117.5M | $111.9M | $78.0M | $83.6M |
| Shareholders' equity | $50.3M | $28.4M | $6.38M | −$18.2M | −$3.18M | $9.46M | $21.4M | −$1.67M |
| Cash flow | ||||||||
| Operating cash flow | −$18.0M | — | −$25.1M | −$21.2M | −$22.7M | −$21.3M | −$22.5M | −$15.9M |
| Capital expenditure | $213.0K | — | $448.0K | $98.0K | $8.00K | $3.00K | — | — |
| Free cash flow | −$18.3M | — | −$25.5M | −$21.3M | −$22.7M | −$21.3M | — | — |
From Fractyl Health's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Fractyl Health
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1 (GLP-1).
Source: Wikipedia — Fractyl Health
- Headquarters
- Burlington, Massachusetts From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with GUTS
- GOSS Gossamer Bio Inc
- GPCR Structure Therapeutics
- GRAL Grail Inc
- GRDN Guardian Pharmacy Services Inc Cla
- GYRE Gyre Therapeutics Inc
- HAE Haemonetics Corp
- HALO Halozyme Therapeutics
- HCAT Health Catalyst Inc